ES2792923T3 - Métodos para el tratamiento de la retinopatía diabética proliferativa - Google Patents

Métodos para el tratamiento de la retinopatía diabética proliferativa Download PDF

Info

Publication number
ES2792923T3
ES2792923T3 ES13784718T ES13784718T ES2792923T3 ES 2792923 T3 ES2792923 T3 ES 2792923T3 ES 13784718 T ES13784718 T ES 13784718T ES 13784718 T ES13784718 T ES 13784718T ES 2792923 T3 ES2792923 T3 ES 2792923T3
Authority
ES
Spain
Prior art keywords
retinal
retina
patient
compound
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13784718T
Other languages
English (en)
Spanish (es)
Inventor
Claes Bavik
Susan Henry
Ryo Kubota
Vladimir Kuksa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kubota Vision Inc
Original Assignee
Acucela Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acucela Inc filed Critical Acucela Inc
Application granted granted Critical
Publication of ES2792923T3 publication Critical patent/ES2792923T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ES13784718T 2012-05-04 2013-05-03 Métodos para el tratamiento de la retinopatía diabética proliferativa Active ES2792923T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261643178P 2012-05-04 2012-05-04
US201261643051P 2012-05-04 2012-05-04
US201261643058P 2012-05-04 2012-05-04
US201361781907P 2013-03-14 2013-03-14
PCT/US2013/039562 WO2013166449A2 (en) 2012-05-04 2013-05-03 Methods for the treatment of diabetic retinopathy and other ophthalmic diseases

Publications (1)

Publication Number Publication Date
ES2792923T3 true ES2792923T3 (es) 2020-11-12

Family

ID=49515046

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13784718T Active ES2792923T3 (es) 2012-05-04 2013-05-03 Métodos para el tratamiento de la retinopatía diabética proliferativa

Country Status (18)

Country Link
US (4) US9957224B2 (enExample)
EP (2) EP3741742A1 (enExample)
JP (6) JP2015518491A (enExample)
KR (1) KR20150013240A (enExample)
CN (3) CN104411678A (enExample)
AU (1) AU2013256029A1 (enExample)
BR (1) BR112014027571B1 (enExample)
CA (1) CA2872433C (enExample)
EA (1) EA201492031A1 (enExample)
ES (1) ES2792923T3 (enExample)
HK (2) HK1203478A1 (enExample)
IL (1) IL235446A0 (enExample)
MX (2) MX386024B (enExample)
PH (1) PH12014502449A1 (enExample)
SG (1) SG11201407162SA (enExample)
TW (1) TW201406707A (enExample)
WO (1) WO2013166449A2 (enExample)
ZA (1) ZA201408592B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110089C2 (uk) * 2007-10-05 2015-11-25 Ак'Юсела Інк. Алкоксисполуки для лікування нейродегенеративних хвороб
EP2448569B1 (en) * 2009-07-02 2021-10-27 Acucela, Inc. Pharmacology of visual cycle modulators
JP2015505536A (ja) 2012-01-20 2015-02-23 アクセラ インク． 疾患の処置のための置換された複素環化合物
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
MX2015012435A (es) * 2013-03-12 2016-01-25 Acucela Inc Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmicos.
EP3195838B1 (en) 2013-03-14 2018-08-22 Optimedica Corporation Laser capsulovitreotomy
WO2015157644A1 (en) * 2014-04-10 2015-10-15 Lankenau Institute For Medical Research Methods and compositions for the treatment of ocular diseases and disorders
US10792374B2 (en) 2015-10-09 2020-10-06 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
AU2018223810B2 (en) * 2017-02-27 2022-04-21 Case Western Reserve University Visual cycle modulators
CN111526779B (zh) * 2017-12-28 2023-07-11 株式会社尼康 图像处理方法、图像处理程序、图像处理装置、图像显示装置、以及图像显示方法
MX2018008165A (es) * 2018-06-29 2019-12-30 Centro De Retina Medica Y Quirurgica S C Sistema portátil para la identificación de casos potenciales de edema macular diabético mediante procesamiento de imagen e inteligencia artificial.
EP3817808A4 (en) 2018-07-07 2022-04-06 Acucela Inc. Device to prevent retinal hypoxia
CN118403291A (zh) 2018-07-30 2024-07-30 奥克塞拉有限公司 用于延缓近视进展的电子接触透镜的光学设计
WO2020078865A1 (en) * 2018-10-16 2020-04-23 F. Hoffmann-La Roche Ag Use of akt inhibitors in ophthalmology
US11154540B2 (en) * 2018-10-19 2021-10-26 Medicinova, Inc. Methods of treating ophthalmic disease/disorder or injury with ibudilast
US12256994B2 (en) * 2019-05-31 2025-03-25 Nikon Corporation Systems and methods for combining fundus images of an eye
EP4003250A4 (en) 2019-07-31 2023-08-23 Acucela Inc. DEVICE FOR PROJECTING IMAGES ONTO THE RETINA
US11733545B2 (en) 2019-09-16 2023-08-22 Acucela Inc. Assembly process for an electronic soft contact lens designed to inhibit progression of myopia
CN115336113A (zh) 2020-02-21 2022-11-11 奥克塞拉有限公司 用于电子隐形眼镜的充电盒
CN111617313B (zh) * 2020-04-29 2022-09-06 天津医科大学眼科医院 一种眼用线性凝胶在作为临床孔源性视网膜脱离药物方面中的应用
AU2021270577A1 (en) 2020-05-13 2022-12-08 Acucela Inc. Electro-switchable spectacles for myopia treatment
CN115916331A (zh) 2020-06-08 2023-04-04 奥克塞拉有限公司 在周边视网膜上投射散焦图像来治疗屈光不正
JP2023528307A (ja) 2020-06-08 2023-07-04 アキュセラ インコーポレイテッド 周辺脱焦点化を使用して進行性屈折異常を治療するための貼付式デバイス
KR20230020510A (ko) 2020-06-08 2023-02-10 어큐셀라 인코포레이티드 난시 치료를 위한 비대칭 투사 렌즈
US11281022B2 (en) 2020-06-10 2022-03-22 Acucela Inc. Apparatus and methods for the treatment of refractive error using active stimulation
US11209672B1 (en) 2021-04-06 2021-12-28 Acucela Inc. Supporting pillars for encapsulating a flexible PCB within a soft hydrogel contact lens
US11366341B1 (en) 2021-05-04 2022-06-21 Acucela Inc. Electronic case for electronic spectacles
CA3218950A1 (en) * 2021-05-16 2022-11-24 Metanoia Bio Inc. Methods and compositions for treating ocular neovascular disease
US20240274295A1 (en) * 2021-06-03 2024-08-15 Osaka University Method for screening for retinopathy of prematurity, apparatus for screening for retinopathy of prematurity, and learned model
US20240408056A1 (en) * 2023-06-12 2024-12-12 Synaptogenix, Inc. Methods for repairing nerve damage using pkc activating therapeutic agents

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US20030181531A1 (en) * 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
BR0213975A (pt) * 2001-11-09 2005-05-10 Eyetech Pharmaceuticals Métodos para tratar doenças neovasculares oculares
KR20070011379A (ko) * 2004-03-17 2007-01-24 라스 미카엘 라르센 시각 사이클 억제에 의한 망막증의 예방
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
WO2008131368A2 (en) * 2007-04-20 2008-10-30 Acucela Inc. Styrenyl derivative compounds for treating ophthalmic diseases and disorders
BRPI0812755A2 (pt) * 2007-06-29 2014-09-30 Acucela Inc Compostos de derivados de fenil alquinila para tratar doenças, e desordens oftálmicas
UA110089C2 (uk) 2007-10-05 2015-11-25 Ак'Юсела Інк. Алкоксисполуки для лікування нейродегенеративних хвороб
GB2455176A (en) 2007-11-01 2009-06-03 Acucela Inc Amine derivatives useful for treating ophthalmic diseases and disorders
KR101395952B1 (ko) 2008-09-05 2014-05-21 어큐셀라 인코포레이티드 안과 질환 및 장애 치료를 위한 황-연결 화합물
CN102197023B (zh) * 2008-10-22 2015-12-16 奥克塞拉有限公司 治疗眼科疾病和紊乱的化合物
EP2448569B1 (en) * 2009-07-02 2021-10-27 Acucela, Inc. Pharmacology of visual cycle modulators
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法

Also Published As

Publication number Publication date
MX2014013341A (es) 2015-06-02
JP2015518491A (ja) 2015-07-02
WO2013166449A3 (en) 2014-01-30
HK1203478A1 (en) 2015-10-30
US9957224B2 (en) 2018-05-01
PH12014502449A1 (en) 2015-01-12
WO2013166449A2 (en) 2013-11-07
CN104411678A (zh) 2015-03-11
BR112014027571B1 (pt) 2021-08-31
HK1246646A1 (zh) 2018-09-14
US20140039048A1 (en) 2014-02-06
CA2872433A1 (en) 2013-11-07
BR112014027571A2 (pt) 2017-07-18
CA2872433C (en) 2022-06-28
KR20150013240A (ko) 2015-02-04
JP2020023535A (ja) 2020-02-13
TW201406707A (zh) 2014-02-16
CN116850163A (zh) 2023-10-10
MX386024B (es) 2025-03-18
MX2020001835A (es) 2021-09-09
JP2025069362A (ja) 2025-04-30
US20210171435A1 (en) 2021-06-10
US11795136B2 (en) 2023-10-24
US20180346407A1 (en) 2018-12-06
JP2021075576A (ja) 2021-05-20
EP2844636B1 (en) 2020-04-22
CN107865830A (zh) 2018-04-03
US10730825B2 (en) 2020-08-04
EP2844636A4 (en) 2016-03-09
ZA201408592B (en) 2017-09-27
AU2013256029A1 (en) 2014-12-04
SG11201407162SA (en) 2014-11-27
EP2844636A2 (en) 2015-03-11
JP2023059991A (ja) 2023-04-27
US20240308951A1 (en) 2024-09-19
IL235446A0 (en) 2014-12-31
JP2018024702A (ja) 2018-02-15
EP3741742A1 (en) 2020-11-25
EA201492031A1 (ru) 2015-05-29

Similar Documents

Publication Publication Date Title
ES2792923T3 (es) Métodos para el tratamiento de la retinopatía diabética proliferativa
Ostrin et al. IMI—the dynamic choroid: new insights, challenges, and potential significance for human myopia
JP2023509336A (ja) 過剰血管新生に関連する眼疾患を治療する化合物
KR102384118B1 (ko) 황반변성 예방 또는 치료용 조성물
JP7615139B2 (ja) 萎縮型加齢黄斑変性（ａｍｄ）又は萎縮型ａｍｄに続発する地図状委縮の治療用抗ｃ５剤
US20240342202A1 (en) Methods of Treating Retinal Vasculopathies
HK40038867A (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
KR102294439B1 (ko) 황반변성 예방 또는 치료용 조성물
CN116270442B (zh) 一种用于矫正近距离视力的眼用制剂
Abdelmoneem et al. Comparison of Ranibizumab alone versus Ranibizumab with Targeted Retinal Laser for Branch Retinal Vein Occlusion with Macular Oedema.
Ahmed Peribulbar injection of triamcinolone acetonide as an outpatient clinic procedure in the management of mild to moderate macular edema
JP2016069330A (ja) 低酸素関連眼疾患のインビボ用診断薬及び治療用組成物
Sgambellone Histamine H3 receptor (H3R) antagonist-Nitric Oxide (NO) donor hybrid compounds as a new therapeutic strategy for the treatment of glaucoma and retinal neuroprotection
Williamson et al. 14 Medical Therapy for Glaucoma
Dada et al. Medical Management of glaucoma
Palanivelu et al. Various Syndromes with Benign Intraocular Tumors
Kuriakose Management of Macular Edema Secondary to Branch Retinal Vein Occlusion with Intravitreal Bevacizumab and Macular Grid Laser
Ghosh To forecast the changing trends in the treatment of glaucoma by 2020